Handok

Handok is a prominent pharmaceutical company based in Korea, actively engaged in the healthcare sector. The company specializes in the development of prescription medications, over-the-counter (OTC) drugs, medical devices, and in-vitro diagnostics. Handok focuses on creating products that target significant health issues, including diabetes, hypertension, and cardiovascular diseases. Through its extensive research and development efforts, Handok aims to enhance patient care and contribute to advancements in medical treatments.

Young-jin Kim

Chairman

3 past transactions

Spark Biopharma

Series B in 2021
SPARK BioPharma Co., Ltd. was established in Seoul National University in January 2016 based on the unique drug molecule diversity technology, the image-based screening technology using the unique fluorescent skeleton probe, and the target protein identification technology in the initial drug development stage. We are currently exploring and developing new drug candidates using these three core technologies, and we will continue to accelerate the development of new drugs and increase the success rate through strategic cooperation research with domestic and overseas research institutes and pharmaceutical institutions. '

WELT

Series B in 2021
From Wristworn to Waistworn: WELT, the Smart Belt for Fashion & Healthcare WELT is a 'Smart Fashion Belt' that manages users’ wellness. We encourage users to embrace healthy habits while keeping in style. We promise to help the wearer better track food intake, keep tabs on the activity level, and manage weight. To do this, WELT keeps check on the overall health by measuring (1)Waist size, (2)Steps, (3)Sitting time, and (4)Overeating habits. To help users avoid metabolic risks factors, custom messages to manage these risks are given through the app via BLE. Also, its elegant design makes it look just like a regular, leather belt. Battery is rechargeable, and can stand up to more than 7 days.

BIOMx

Series B in 2019
BiomX discovers and develops innovative microbiome therapeutics. The Company's mission is to develop novel therapeutics for preventing and treating diseases in which microbiome imbalances have been implicated. BiomX's microbiome modulation technologies are based on the cutting-edge innovative research of its scientific collaborators: Professor Rotem Sorek, PhD and Dr. Eran Elinav, MD, PhD both of the Weizmann Institute of Science and Professor Timothy K. Lu, MD, PhD of the Massachusetts Institute of Technology.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.